Research progress in NSCLC with co-existence of EGFR mutation and EML4-ALK rearrangement

Abstract

In recent decades, the clinical application of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) has improved the survival of patients with non-small cell lung cancer(NSCLC), which also remarkably promote the standardization of EGFR and EML4-ALK testing in patients with advanced lung cancer and the development of individualized targeted therapy for advanced NSCLC.However, the co-existing mutation of EGFR and ALK gene is rare compared with single mutation of them, the clinical features and optimal targeted therapy of double-positive patients are not clear yet.Therefore, this paper aims to review the reports of NSCLC patients with double EGFR mutation and EML4-ALK rearrangement. Key words: Carcinoma, non-small-cell lung; Receptor, epidermal growth factor; Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase; Co-existing mutation